AOD-9604 vs Semaglutide
HGH Fragment · GLP-1 Receptor Agonist
Here is how these two compounds compare, based on published research, not marketing claims.
AOD-9604
An engineered growth hormone fragment analog studied in 2000s Phase 2 trials for obesity; the 2006 to 2007 Phase 2b trial in 536 obese adults did not meet primary endpoint; commercial development as a drug discontinued.
Semaglutide
The FDA-approved GLP-1 medication with completed Phase 3 trial programs across type 2 diabetes (SUSTAIN), chronic weight management (STEP), and cardiovascular outcomes (SELECT).
AOD-9604
20 studies
2 human trials
Not FDA-Approved
Semaglutide
4520 studies
39 human trials
FDA-Approved
What it does
AOD-9604
A modified analog of human growth hormone fragment 176-191 with a tyrosine residue added at the N-terminus for proteolytic stability. Developed by Metabolic Pharmaceuticals through Phase 2 trials in the 2000s for obesity. The 2006 to 2007 Phase 2b trial in 536 obese adults did not meet its primary endpoint for weight loss over 12 weeks. Commercial development as a drug was discontinued. The compound received Generally Recognized As Safe (GRAS) status as an ingredient. Not FDA-approved as a drug.
Semaglutide
Holds the first FDA approval for a weekly GLP-1 drug with cardiovascular outcomes data. Marketed as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as an oral tablet. Reduces appetite and slows how fast food leaves the stomach through hypothalamic GLP-1 receptor activation. Two major trials (SUSTAIN-6 in diabetic patients and SELECT in non-diabetic adults with obesity) showed reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death), not just weight or blood sugar. That cardiovascular evidence is what made the GLP-1 class category-shifting in metabolic medicine.
How it works
AOD-9604
A modified version of the human growth hormone 176-191 fragment. The added N-terminal tyrosine residue improves resistance to proteolytic breakdown, extending the compound's stability versus the parent fragment. The proposed mechanism mirrors fragment 176-191: selective adipocyte lipolysis and hepatic fat oxidation without engaging the IGF-1 anabolic pathway. Phase 2 trial data showed measurable lipolytic effects but did not establish clinically meaningful weight loss versus placebo at the doses tested.
Semaglutide
A modified copy of GLP-1, a hormone the body releases naturally after eating. It activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full, slows how fast the stomach empties, and helps the pancreas release insulin when blood sugar is high. The modification keeps it active in the body for about a week, instead of the few minutes natural GLP-1 lasts.
How often
AOD-9604
Phase 2 trial protocols tested both daily oral and daily subcutaneous formulations. The Phase 2b trial used a daily oral formulation over 12 weeks. AOD-9604 is not FDA-approved as a drug for any weight management indication; clinical availability for weight management does not exist.
Semaglutide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for the injectable formulation. The SUSTAIN, STEP, and SELECT trial protocols used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Semaglutide is marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral formulation for type 2 diabetes.
How strong
AOD-9604
Phase 2b trial (2006 to 2007) in 536 obese adults did not meet primary endpoint for weight loss versus placebo over 12 weeks. Smaller earlier Phase 2 trials reported variable lipolytic effects but did not establish a consistent magnitude of weight loss. The compound's evidence base for weight management is far smaller and structurally different from current GLP-1 medications, which have completed Phase 3 programs with double-digit percentage mean weight reductions.
Semaglutide
Strong appetite suppression. In the STEP obesity trials, average weight loss reached 15-17% at the highest dose over 68 weeks. The effect builds gradually as the dose titrates up over the first months of treatment.
Main tradeoff
AOD-9604
AOD-9604 has the most complete clinical trial program of any peptide in the growth hormone fragment lipolytic class, including a Phase 2b trial that was structurally rigorous. The Phase 2b primary endpoint failure is the structural limitation: the trial did not establish clinically meaningful weight loss at the doses and duration tested. Compounded versions sold in research-peptide markets are not FDA-regulated as drugs. The compound's GRAS status applies to ingredient use, not therapeutic use.
Semaglutide
Strong evidence base from large completed Phase III programs (STEP for weight, SUSTAIN and PIONEER for diabetes, SELECT for cardiovascular outcomes). Common side effects are GI: nausea, vomiting, diarrhea, usually transient and dose-dependent. Tirzepatide produces larger average weight loss in head-to-head trials, but semaglutide has the longer cardiovascular outcomes data. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with tirzepatide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Best for
AOD-9604
- Research interest in the GH-fragment lipolytic class development arc
- Understanding why this class did not advance to Phase 3 development for weight management
- Researchers comparing the engineered analog to the parent fragment 176-191
Semaglutide
- Adults with type 2 diabetes seeking glycemic control with cardiovascular outcomes data (SELECT trial)
- Adults with overweight or obesity who want the GLP-1 with the longest real-world safety record
- Clinical contexts prioritizing established cardiovascular outcomes over maximal weight reduction
How to choose
A good fit for AOD-9604
- Research interest in the growth hormone fragment lipolytic class development arc
- Understanding why the GH-fragment class did not advance to Phase 3 for weight management
- Studying the AOD-9604 Phase 2 trial program and Phase 2b outcome
A good fit for Semaglutide
- Clinical decision today for type 2 diabetes management or chronic weight management
- Need an FDA-approved compound with completed cardiovascular outcomes data
- Decision contexts where Phase 3 trial evidence and FDA approval are required
Consider both across time
AOD-9604 and semaglutide are not in the same evidence tier despite both having been studied for weight outcomes. AOD-9604 reached Phase 2 in the 2000s under Metabolic Pharmaceuticals and the 2006 to 2007 Phase 2b trial in 536 obese adults did not meet primary endpoint for weight loss; commercial development as a weight management drug was discontinued thereafter. Semaglutide reached FDA approval through completed Phase 3 programs and continues as the dominant FDA-approved option for both type 2 diabetes and chronic weight management. The mechanisms are also entirely different: AOD-9604 proposes lipolytic activity through growth hormone fragment activity; semaglutide activates the GLP-1 receptor for appetite suppression and gastric emptying delay. Users searching this comparison are typically encountering AOD-9604 in research-peptide markets and asking whether it represents an alternative to semaglutide. The honest answer is that AOD-9604 is a research compound with a discontinued development program; semaglutide is the FDA-approved standard.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Adipocyte (fat cell)
- Adipocyte (fat cell) engages Lipolytic Signaling
- Lipolytic Signaling connects to Fat Mobilization
- Lipolytic Signaling connects to Hepatic Fat Oxidation
- Fat Mobilization connects to Body Fat Reduction (Phase 2 endpoint); Hepatic Fat Oxidation connects to Body Fat Reduction (Phase 2 endpoint)
- GLP-1 Receptor
- GLP-1 Receptor activates GLP-1 Signaling
- GLP-1 Signaling connects to Appetite + Gastric Emptying
- GLP-1 Signaling connects to Glucose Control
- Appetite + Gastric Emptying connects to Weight + Glycemic Outcomes; Glucose Control connects to Weight + Glycemic Outcomes
AOD-9604 engages a proposed adipocyte lipolytic mechanism without engaging the IGF-1 anabolic pathway; trial data did not establish clinically meaningful weight loss in Phase 2b.
Semaglutide activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full and slows how fast the stomach empties.
Research Evidence
Semaglutide carries orders of magnitude more clinical evidence than AOD-9604. Semaglutide's evidence base spans completed Phase 3 programs for type 2 diabetes (SUSTAIN, PIONEER), chronic weight management (STEP, with 15 to 17 percent mean body weight reduction at 68 weeks), and cardiovascular outcomes (SELECT), plus years of post-marketing surveillance. AOD-9604's evidence base is the early-2000s Phase 2 trial program by Metabolic Pharmaceuticals, including the structurally rigorous Phase 2b trial in 536 obese adults from 2006 to 2007. The Phase 2b trial did not meet primary endpoint for weight loss versus placebo over 12 weeks; commercial development as a weight management drug was discontinued. The compound subsequently received Generally Recognized As Safe (GRAS) status as an ingredient but no FDA approval as a drug. The two evidence bases are not comparable in scope, depth, or regulatory outcome.
- 1.
For evidence-based weight management, semaglutide has an incomparably stronger research foundation.
- 2.
For understanding fat metabolism mechanisms, AOD-9604 provides interesting preclinical data about HGH fragment activity.
- 3.
For clinical decision-making, semaglutide is the only compound here with proven efficacy in controlled trials.
- 4.
AOD-9604's newer osteoarthritis research direction may prove more promising than its original obesity indication.
Key Limitations
- •This comparison is inherently lopsided, one compound has FDA Approved evidence, the other has Animal Studies.
- •AOD-9604's clinical program for obesity was discontinued after failing its efficacy endpoint.
- •Comparing an FDA-approved medication to a discontinued research compound has limited clinical utility.
- •Cost, access, and prescription requirements differ fundamentally between these options.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
AOD-9604
"AOD-9604 burns fat without affecting muscle"
Plausible but modest effect
"AOD-9604 helps with joint pain too"
Insufficient evidence
Semaglutide
"I lost 30+ pounds on Ozempic without changing anything else"
Supported by evidence
"Ozempic face is a real thing. I look ten years older"
Supported by evidence
"The nausea goes away after a few weeks"
Supported by evidence
Safety Comparison
Semaglutide has years of post-marketing surveillance from millions of prescriptions; common adverse events are gastrointestinal (nausea, vomiting, diarrhea, usually transient and dose-dependent); the FDA boxed warning for thyroid C-cell tumors applies. AOD-9604 has Phase 2 trial safety data with no major signals reported in the published trial program, but the absence of post-marketing surveillance data and the absence of FDA drug-status oversight represents a structural safety-information gap. Compounded versions of AOD-9604 sold in research-peptide markets are not FDA-regulated as drugs; the GRAS ingredient status does not extend to therapeutic use. The two compounds are not interchangeable from a safety perspective because they have entirely different regulatory oversight and entirely different post-approval data accumulation.
AOD-9604
Limited human safety data. Phase IIb trial showed no serious safety concerns but also failed to demonstrate statistically significant weight loss. Generally considered well-tolerated.
Semaglutide
Extensively characterized. GI side effects (nausea, vomiting) are common but typically transient. Rare risks include pancreatitis. Thousands of patient-years of safety data.
What the Research Suggests
There is no evidence-based case for choosing AOD-9604 over semaglutide for weight management. Semaglutide has proven efficacy, FDA approval, and cardiovascular outcome data. AOD-9604 failed its pivotal trial. This comparison exists because both appear in peptide therapy discussions, not because they are equivalent options.